H1O Stock Chart & Stats
€0.43
€0.00(0.00%)
At close: 4:00 PM EDT
€0.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.43 - €0.43
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€13.13M
Enterprise Value€3.50M
Total Cash (Recent Filing)€8.80M
Total Debt (Recent Filing)€22.55K
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.80
Shares Outstanding7,018,528
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.97Price Target Upside2917.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage & Recent Positive EquityVery low reported leverage and a return to positive equity provide durable financial flexibility. This reduces insolvency risk, supports the ability to raise incremental capital on better terms, and gives management runway to execute strategic shifts without immediate debt servicing pressure.
Healthy Gross MarginsNear-50% gross margins indicate favorable unit economics at the product level. If management can control operating spend and scale revenue, these margins create room for operating leverage, making a path to sustainable profitability plausible over multiple quarters to years.
Strategic Repositioning And Capital-structure TighteningA formal strategic pivot into AI HR analytics and shareholder-approved share reduction are structural moves. Repositioning opens a new addressable market and product roadmap while tightening the capital structure can reduce future dilution risk, aligning incentives for long-term value creation.
Bears Say
Sharp TTM Revenue DeclineA near-50% TTM revenue decline from an already small base signals structural demand or execution issues. Declining topline undermines scale economics, compresses coverage of fixed costs, and makes sustained investment in growth or R&D harder without clear evidence of revenue stabilization.
Consistent Negative Cash Flow / Cash BurnMulti-year negative operating and free cash flow indicates the business does not self-fund operations and needs recurring external capital. Persistent cash burn constrains strategic flexibility, risks dilution through financing, and heightens vulnerability if capital markets or execution falter.
Large Net Losses And Poor ReturnsExtremely negative net margins and persistently poor returns show the company is not converting revenue into profit or shareholder value. Over the medium term this erodes investor confidence, limits reinvestment potential, and increases the odds of restructuring or further equity raises to sustain operations.
H1O FAQ
What was Vyome Holdings’s price range in the past 12 months?
Vyome Holdings lowest stock price was €0.43 and its highest was €0.43 in the past 12 months.
What is Vyome Holdings’s market cap?
Vyome Holdings’s market cap is €13.13M.
When is Vyome Holdings’s upcoming earnings report date?
Vyome Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 105 days.
How were Vyome Holdings’s earnings last quarter?
Vyome Holdings released its earnings results on May 28, 2026. The company reported -€0.132 earnings per share for the quarter, the consensus estimate of -€0.132 by €0.
Is Vyome Holdings overvalued?
According to Wall Street analysts Vyome Holdings’s price is currently Undervalued.
Does Vyome Holdings pay dividends?
Vyome Holdings does not currently pay dividends.
What is Vyome Holdings’s EPS estimate?
Vyome Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vyome Holdings have?
Vyome Holdings has 7,018,528 shares outstanding.
What happened to Vyome Holdings’s price movement after its last earnings report?
Vyome Holdings reported an EPS of -€0.132 in its last earnings report, expectations of -€0.132. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vyome Holdings?
Currently, no hedge funds are holding shares in DE:H1O
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
H1O Stock 12 Month Forecast
Average Price Target
€12.97
▲(2917.27% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
Collplant Holdings
―
Dermata Therapeutics
―
Azitra Inc
―
Polyrizon Ltd.
―









